ADVANCED SOLID TUMOR

This early-phase study tests a new drug called DM919, given alone or with another drug (pembrolizumab), in 160 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. P…

This early-phase study tests a new treatment called KSQ-001EX for people with advanced solid tumors like melanoma, lung, or head and neck cancers. The treatment uses a patient's own immune cells, which are modified in a lab to work better against cancer. The main goal is to see i…

This early-stage study tests a new drug called vilastobart, alone or with another drug (atezolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drugs shrink tumors. About 136 adults will…

This study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to find a safe dose and see if the drug can shrink tumors. About 1,123 participants will ta…

This study tests a new drug, YL201, in about 990 adults with advanced solid tumors (like lung, prostate, or liver cancer) that have not responded to other treatments. The trial has two parts: first to find the best dose, then to see how well it works and how safe it is. The goal …

This early-stage study tests a new drug called SHR-4712 in 15 people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and how the body processes it. Participants receive the drug until their disease worsens or s…

This early-phase study tests an experimental drug called MOMA-313, given alone or with another drug (olaparib), in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the dru…

This early-phase study tests a new drug called BGB-C354, which delivers a cancer-killing agent directly to tumor cells. It is given alone or with another drug (tislelizumab) that helps the immune system attack cancer. The study includes about 120 adults with advanced solid tumors…

This early-phase study tests a new drug, NTX-1088, which blocks a protein on cancer cells that helps them hide from the immune system. The trial includes about 90 adults with advanced solid tumors that have not responded to standard treatments. Participants receive NTX-1088 alone…

This early-phase study tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread. The main goals are to check safety and find the highest safe dose. Researchers will also measure drug levels in blood and urine and look at immune system changes.

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with cancers like pancreatic, lung, or c…

This early-stage study tests a new drug called RP3, alone or with an immunotherapy, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is not a cure, but aims to control the diseas…

This study tests an experimental drug called INCB099280 in 73 people with advanced solid tumors (like liver or skin cancer) who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. Participants must have measurabl…

This early-stage study tests a new drug called TORL-3-600 in 70 adults with advanced solid tumors or colorectal cancer that has not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants must have…

This early-stage study tests a new drug called TORL-2-307-ADC in people with advanced solid tumors, including stomach, pancreas, and esophageal cancers. The main goals are to find a safe dose and check for side effects. About 163 participants will receive the drug to see if it ca…

This early-stage study tests an experimental drug called CLN-619, given alone or with pembrolizumab, in adults with advanced solid tumors (including non-small cell lung cancer). The main goals are to check safety and see if the drug shrinks tumors. About 440 participants will be …

This early-phase study tests a new oral drug (BGB-15025) that targets a protein called HPK1 to help the immune system fight cancer. It is given alone or with an immunotherapy (tislelizumab) to about 157 people with advanced solid tumors that have not responded to standard treatme…

This study tests a new drug called ANV600, alone or with another drug (pembrolizumab), in 240 adults with advanced solid tumors that have not responded to other treatments. The goal is to check safety and see if the drug shrinks tumors. Participants must be in fairly good health …

This study tests a new drug called JSKN003 in Chinese adults with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the safest dose and see if the drug can shrink tumors. About 725 participants will receive the drug intravenously every th…

This early-phase study tests a new drug called LP-184 in 64 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their …

This study tests an experimental oral drug called IMM-1-104 in people with advanced solid tumors that have RAS mutations. The goal is to find the best dose and see if it can shrink tumors or slow their growth. About 209 adults with pancreatic cancer, melanoma, or lung cancer will…

This study tests whether combining two drugs, lurbinectedin and berzosertib, can shrink tumors in people with small cell lung cancer or high-grade neuroendocrine cancers. These cancers often stop responding to standard chemotherapy. The trial involves 37 adults and aims to find t…

This study tests an experimental drug called LM-108 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to help the immune system fight cancer. The trial involves about 392 adults and aims to find safe doses and see if th…

This study tests a new drug called NUV-1511 in adults with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors. The study includes people with certain breast, prostate, pancreatic, and ovarian can…

This study tests a new drug called BT8009, given alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tu…

This early-phase study tests a new drug called WTX-124, either alone or combined with pembrolizumab, in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose, while also seeing if the drug …

This early-phase study tests a new drug called M9466, which blocks a protein (PARP1) that helps cancer cells repair themselves. The goal is to see if it is safe and tolerable when given alone or with other drugs (tuvusertib or an ARPi) in people with advanced solid tumors that ha…

This study tests a new drug called BT7480, alone or with another drug (nivolumab), in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or slow their growth. About 200 participants wil…

This early-stage study tests an oral drug called ATRN-119 in 132 people with advanced solid tumors that have specific DNA repair mutations. The main goal is to check safety and how the drug moves through the body, while also looking for signs it may shrink tumors. Participants mu…

This early-phase study tests a new drug called TTX-MC138 in 16 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the drug can shrink or stabilize tumors. This is not a cure, but aims to control the dise…

This early-phase study tests a new drug called RMC-6291 in adults with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to find a safe dose and see how the body handles the drug. About 222 people with lung, colorectal, or pancreatic cancer that has not r…

This study tests a new drug called MHB036C in 200 adults with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants will receive the drug and be monitored for side effects and how the…

This early-stage study tests a new drug called PRJ1-3024 in about 39 people with advanced solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug migh…

This study tests an experimental drug called TransCon IL-2 β/γ, given alone or with other cancer treatments, for adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find safe doses and check for side effects. About 320 partici…

This early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor shrinkage an…

This early-phase study tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study tests a new drug called MHB039A in about 196 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look at how the drug moves through the body and whether it h…

This early-phase study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to target and attack cancer cells while sparing healthy ones. The study will check if the drug is safe and what dose wor…

This early-stage study tests two drugs, niraparib and neratinib, together in people with advanced solid tumors or ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find the safest dose and see if the combination can stop the cancer from growing for a…

This study tests an experimental drug called KL590586 in people with advanced solid tumors that have a specific change in the RET gene. The goal is to see if the drug is safe and can shrink tumors. About 414 adults whose cancer has not responded to standard treatments will take t…

This early-phase trial tests a combination of three common drugs—metformin, digoxin, and simvastatin—in people with advanced pancreatic cancer or other solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects…

This early-phase study tests an experimental tablet called BB3008 in about 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety, find the best dose, and see how food affects it. Participants take the pill by m…

This study tests a new drug called ZG005 in 50 adults with advanced solid tumors that did not respond to or could not tolerate standard treatments. The main goal is to see if the drug shrinks tumors and to check for side effects. Participants receive the drug and are monitored cl…

This study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. The trial enrolled 8 participants who had steroid-dependent immune-related side effects. The goal is to see if these drugs can con…

This study looks at whether a blood test (called a liquid biopsy) can be used during regular cancer care to find tumor DNA and help doctors choose treatments. About 159 adults with advanced solid tumors will give blood samples as part of their routine visits. Researchers will com…